晶豐明源(688368.SH):2022年度擬向銀行等金融機構申請綜合授信總額不超12億元
格隆匯2月23日丨晶豐明源(688368.SH)公佈,公司第二屆董事會第二十一次會議決議,審議通過《關於向銀行申請2022年度綜合授信額度的議案》
為滿足公司生產經營和發展需要,為保證公司業務正常開展,公司及子公司2022年度擬向銀行等金融機構申請綜合授信總額不超過人民幣12億元。綜合授信品種包括但不限於貸款、承兑匯票、貼現、信用證、押匯、保函、代付、保理等。
授信額度自董事會通過之日起至下一年度董事會審批新的額度事項之日前可循環使用,具體以公司及子公司與各家銀行簽署的授信合同約定為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.